ERBB2 and rhabdomyosarcoma: Later, Hegde et al. reported on 13 patients with progressive, metastatic, or recurrent HER2+ sarcoma (osteosarcoma, rhabdomyosarcoma, synovial sarcoma) who were treated with HER2-directed CAR T-cells with varying lymphodepleting regimens [23].